The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC).
 
Rafael Morales-Barrera
Consulting or Advisory Role - AstraZeneca; MSD; Sanofi
Speakers' Bureau - Asofarma; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Johnson & Johnson; Lilly; MSD; Roche/Genentech; Sanofi
 
Natalia Vidal Casinello
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Sanofi
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Pierre Fabre
 
Teresa Bonfill
Consulting or Advisory Role - Astellas Oncology; Bristol-Myers Squibb; Merck; Pfizer/EMD Serono; Roche
Travel, Accommodations, Expenses - Bayer; Ipsen; Merck; MSD; Roche
 
Montserrat Domenech
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Lilly; Sanofi
 
Cristina Suarez Rodriguez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Javier Puente
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer; Roche
 
Julia Giner Joaquin
No Relationships to Disclose
 
Mariona Figols
Consulting or Advisory Role - Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck; Novartis; Roche; Sanofi Pasteur
 
Isabel Galante
No Relationships to Disclose
 
Albert Carrion
No Relationships to Disclose
 
Hector Lopez
No Relationships to Disclose
 
Macarena Gonzalez
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Lilly; Lilly; Novartis; Pierre Fabre; Roche
 
Sarai Roche
No Relationships to Disclose
 
Joaquin Mateo
Consulting or Advisory Role - AstraZeneca; Janssen; Roche (Inst)
Speakers' Bureau - Astellas Pharma; AstraZeneca; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Sanofi
Other Relationship - BeiGene
 
Enrique Gallardo Diaz
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; EUSA Pharma; Ipsen; Janssen Oncology; Merck KGaA; Merck KGaA; Pfizer; Roche; Rovi; Sanofi; Shenzen Techdow Pharma
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Ipsen; Janssen Oncology; LEO Pharma; Menarini; Novartis; Novartis; Pfizer; Roche; Rovi; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Janssen; Pfizer; Pierre Fabre; Roche
 
Carlos Fernández Sáez
Travel, Accommodations, Expenses - AstraZeneca
 
Claudia Maria Valverde Morales
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar
Research Funding - Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Ines de Torres
No Relationships to Disclose
 
Juan Morote
No Relationships to Disclose
 
Joan Carles
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Asofarma; Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi/Aventis (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZéneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Roche (Inst)